China's national drug regulator approved Luye Pharma Group's (HKG:2186) Investigational New Drug application for its anti-depression drug LY03021, according to a Monday filing with the Hong Kong bourse.
The medication inhibits the norepinephrine transporter (NET), the dopamine transporter (DAT), and gamma-aminobutyric acid type A receptor-positive allosteric modulator (GABAAR PAM), controlling depression, according to the filing.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
Comments